Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
928.85
-7.50 (-0.80%) Zydus Lifesciences informs about press release
Date: 18-07-2022Zydus Lifesciences has informed that it enclosed a copy of press release dated July 18, 2022 titled ‘Zydus receives final approval from the USFDA for Efinaconazole Topical Solution’.
The above information is a part of company’s filings submitted to BSE.